c-Met receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
The presence of ANAs in blood can be confirmed by a screening test. Although there are many tests for the detection of ANAs, the most common tests used for screening are indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA). Following detection of ANAs, various subtypes are determined.
== Interactions == Anastrozole is thought to have clinically negligible inhibitory effects on the cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2D6, CYP2C8, CYP2C9, and CYP2C19. As a result, it is thought that drug interactions of anastrozole with cytochrome P450 substrates are unlikely. No clinically significant drug interactions have been reported with anastrozole as of 2003. Anastrozole does not affect circulating levels of tamoxifen or its major metabolite N-desmethyltamoxifen. However, tamoxifen has been found to decrease steady-state area-under-the-curve levels of anastrozole by 27%. But estradiol levels were not significantly different in the group that received both anastrozole and tamoxifen compared to the anastrozole alone group, so the decrease in anastrozole levels is not thought to be clinically important.
== See also == Discrete Fourier transform – Function in discrete mathematics − for computing periodicity in evenly spaced data Fourier transform – Mathematical transform that expresses a function of time as a function of frequency Fourier transform spectroscopy – Spectroscopy based on time- or space-domain dataPages displaying short descriptions of redirect targets Least-squares spectral analysis – Periodicity computation method − for computing periodicity in unevenly spaced data
Sources: en.wikipedia.org
Alternate to directly oxidative addition to the peptide, the Pd OACs could also be transferred to the protein through amine-selective acylation reaction via NHS ester. The latter has been applied to selectively label surface lysine residues of a protein (forming PdII-protein OACs) and oligonucleotides (forming PdII-oligonucleotide OACs), which could then be linked to cysteine-containing peptides or proteins.
is electron mobility E is the electric field across the depletion region Dn is the diffusion coefficient for electrons Gn is the rate of generation of electrons Rn is the rate of recombination of electrons Similarly, for holes:
== Function == GnSAF antagonises the positive feedback effects of estradiol on GnRH-induced LH release during the follicular phase. GnSAF inhibits the stimulatory role of estradiol in increasing GnRH-induced de novo synthesis of GnRH receptors in the pituitary. GnRH receptor mRNA levels are low in the presence of high GnSAF bioactivity, which limits the availability of binding sites for GnRH at the pituitary and decreased pituitary sensitivity to GnRH. The moderated GnRH pulse amplitude and frequency is sufficient for maintaining low blood concentrations of LH and protects against premature LH surges and LH hypersecretion. GnSAF also inhibits LH synthesis after the transcription stage and limits stored LH in the pituitary. Whilst the pulse amplitude of LH is reduced by GnSAF, constitutive production of LH is unaffected by GnSAF.
=== Brand names === Finasteride is marketed primarily under the brand names Propecia, for pattern hair loss, and Proscar, for BPH, both of which are products of Merck & Co. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired in June 2006. Merck was awarded a separate patent for the use of finasteride to treat pattern hair loss and it expired in November 2013. Finasteride is also marketed under a variety of other brand names throughout the world.
Sources: en.wikipedia.org
After an incompatible transfusion the recipient may develop an antibody to the antigen and will react to any further incompatible transfusions. This antibody is important because it is the most frequent cause of hemolytic disease of the newborn. Incompatible red blood cells are sometimes given to recipients who will never become pregnant, such as males or postmenopausal women, as long as they do not have an antibody, since the greatest risk of Rh incompatible blood is to current or future pregnancies. For RBCs, type O negative blood is considered a "universal donor" as recipients with types A, B, or AB can almost always receive O negative blood safely. Type AB positive is considered a "universal recipient" because they can receive the other ABO/Rh types safely. These are not truly universal, as other red cell antigens can further complicate transfusions. There are many other human blood group systems and most of them are only rarely associated with transfusion problems. A screening test is used to identify if the recipient has any antibodies to any of these other blood group systems. If the screening test is positive, a complex set of tests must follow to identify which antibody the recipient has by process of elimination. Finding suitable blood for transfusion when a recipient has multiple antibodies or antibodies to extremely common antigens can be very difficult and time-consuming. Because this testing can take time, doctors will sometimes order a unit of blood transfused before it can be completed if the recipient is in critical condition.
The first classification of birds was developed by Francis Willughby and John Ray in their 1676 volume Ornithologiae. Carl Linnaeus modified that work in 1758 to devise the taxonomic classification system currently in use. Birds are usually categorised as a biological class in traditional evolutionary taxonomy. Modern phylogenetic taxonomy places Aves in the clade Theropoda, sometimes with a Linnean rank lower than class, such as subclass or infraclass.
For patients who are exposed to lithium, or plan to stay on the medication throughout their pregnancy, fetal echocardiography is routinely performed to monitor for cardiac anomalies. Pregnancy is associated with a decrease in blood lithium levels (especially in the first and second trimesters), so more frequent monitoring with an increase in dose may be required to maintain control of symptoms. To prevent postpartum psychosis, a higher blood lithium level may be desirable in the third trimester. Initiating lithium immediately after delivery is also effective for preventing postpartum psychosis and postpartum bipolar relapse. This is an acceptable treatment option for women with a history of psychosis limited to the postpartum period. For women with diagnosed bipolar disorder, this provides less protection than maintaining lithium therapy during pregnancy.
American planners had briefly contemplated an invasion of northern Japan from the Aleutian Islands during the autumn of 1943 but rejected that idea as too risky and impractical. They considered the use of Boeing B-29 Superfortresses, on Amchitka and Shemya bases, but rejected the idea. The U.S. military maintained interest in these plans when they ordered the expansion of bases in the western Aleutians, and major construction began on Shemya. In 1945, plans for a possible invasion of Japan via the northern route were shelved. Between 18 and 31 August 1945 Soviet forces invaded the North and South Kurils. The Soviets expelled the entire Japanese civilian population of roughly 17,000 by 1946. Between 24 August and 4 September 1945 the Eleventh Air Force of the United States Army Air Forces sent two B-24s on reconnaissance missions over the North Kuril Islands with the intention of taking photos of the Soviet occupation in the area. Soviet fighters intercepted and forced them away. In February 1945 the Yalta Agreement promised to the Soviet Union South Sakhalin and the Kuril islands in return for entering the Pacific War against the Japanese during World War II. In August 1945 the Soviet Union mounted an armed invasion of South Sakhalin at the cost of over 5,000 Soviet and Japanese lives.
Structured like an association rather than a union, CSEA hesitated to engage in militant labor action or strike, and yet it had a rocky relationship with the state: The union struck for two days at the beginning of April 1972 and won a 5.5 percent pay hike. But the strike and dissatisfaction with CSEA's leadership led some CSEA members to ask for representation by SEIU. With Hardy's strong backing, the newly formed union was able to gather enough signatures on petitions to trigger a representational vote in two of the four units where workers were represented by CSEA, but SEIU lost the vote by a 3-to-1 margin in December 1972. A second strike planned by CSEA leaders was called off after delegates overwhelmingly repudiated a strike resolution supported by the union's leaders. The internal strife led SEIU to once again challenge CSEA for a large unit of New York State public employees. In an election held December 5, 1975, an SEIU-led coalition which included the American Federation of Teachers (AFT), the Laborers' International Union of North America, the International Brotherhood of Teamsters, and several building trades unions was defeated by CSEA, 10,858 to 10,348 with 1,015 voting for neither union. With neither side winning a majority, a second election was held the first week of February 1976, which CSEA won (14,321 to 10,184). But Hardy continued to raid CSEA. CSEA leaders initially sought protection by affiliating with AFSCME.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.